SBFM Insider Trading

Insider Ownership Percentage: 14.70%
Insider Buying (Last 12 Months): $10,000.00
Insider Selling (Last 12 Months): $0.00

Sunshine Biopharma Insider Trading History Chart

This chart shows the insider buying and selling history at Sunshine Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sunshine Biopharma Share Price & Price History

Current Price: $0.93
Price Change: Price Increase of +0.04 (4.49%)
As of 05/17/2024 01:00 AM ET

This chart shows the closing price history over time for SBFM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Sunshine Biopharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/4/2024Steve N SlilatyCEOBuy1,000$10.00$10,000.001,300View SEC Filing Icon  
11/30/2022Camille SebaalyCFOBuy300$76.00$22,800.001,744View SEC Filing Icon  
6/3/2022Camille SebaalyCFOBuy250$122.00$30,500.001,444View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Sunshine Biopharma (NASDAQ:SBFM)

41.98% of Sunshine Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Sunshine Biopharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2024Armistice Capital LLC2,130,000$0.58M0.0%+118.7%8.294%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC974,000$0.31M0.0%-55.6%3.793%Search for SEC Filing on Google Icon
5/17/2022Empery Asset Management LP450,450$1.10M5.2%N/A2.730%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Sunshine Biopharma logo
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.
Read More on Sunshine Biopharma

Today's Range

Now: $0.93
Low: $0.88
High: $1.00

50 Day Range

MA: $4.41
Low: $0.81
High: $10.85

52 Week Range

Now: $0.93
Low: $0.75
High: $67.01

Volume

4,037,246 shs

Average Volume

7,601,855 shs

Market Capitalization

$920,700.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Who are the company insiders with the largest holdings of Sunshine Biopharma?

Sunshine Biopharma's top insider investors include:
  1. Camille Sebaaly (CFO)
  2. Steve N Slilaty (CEO)
Learn More about top insider investors at Sunshine Biopharma.